InflaRx N.V.
NASDAQ:IFRXBiotechnology
-$0.02 today
- Market cap
- $169.47M
- Beta
- 2.44
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$0.59
Volume 1.99M
Average 1.80M
IFRX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
InflaRx N.V.NASDAQ: IFRX
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -€5.49M, compared with -€8.2M a year earlier. Trailing-twelve-month EBITDA was -€42.36M.
Context
- EBITDA amounted to 153976.3% of revenue in FY2025, up 126499.5 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 3 analysts of -€13.65M (+69.8%) for the fiscal year ending Dec 2026, a step up from the +0.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -€5.49M+47.9% QoQ
- Last fiscal yearDec 2025
- -€45.16M+0.9% YoY
- LTMMar 2026
- -€42.36M+1.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +33.0% | +40.3% | +7.3 pp |
| 1 year | +0.9% | +69.8% | +68.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
EUR · from the income statement
- Latest · FY2025
- (45.16M) EUR
- Year-over-year change
- +0.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (45.16M) | +0.9% |
| FY2024 | 2024-12-31 | (45.55M) | -8.3% |
| FY2023 | 2023-12-31 | (42.06M) | -45.8% |
| FY2022 | 2022-12-31 | (28.84M) | +35.8% |
| FY2021 | 2021-12-31 | (44.94M) | — |
EBITDA vs competitors
How IFRX compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1.6% is the 4th highest of 9, against a peer median of -9.2%.
- EBITDA amounts to 144435.8% of revenue for IFRX, versus a peer median of 20388.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$40.18M USD | -45.5% | — | — | |
| LTM Mar 2026 | -€42.36M EUR | +1.6% | — | 144435.8% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | -$44.08M USD | +36.5% | — | — |
| LTM Mar 2026 | -$46.23M USD | +30.8% | — | 4623.1% | |
IMAImageneBio Inc | LTM Mar 2026 | -$51.64M USD | -7.8% | — | — |
| FY2025 | -$54.58M USD | -270.2% | — | 85279.7% | |
| LTM Mar 2026 | -$68.69M USD | -10.6% | — | 36154.2% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | -$84.44M USD | -35.4% | — | — |
| LTM Mar 2026 | -$106.12M USD | +42.0% | — | 106.5% | |
| Peer median (excluding IFRX) | — | -9.2% | — | 20388.7% | |
Competitors are the stored peer set for IFRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 63.09K | 165.79K | 29.33K |
| Cost of Revenue | 0 | 0 | 532.26K | 3.32M | 7.27M |
| Gross Profit | 0 | 0 | (469.17K) | (3.15M) | (7.24M) |
| Gross Margin | — | — | -743.7% | -1900.8% | -24677.9% |
| Research & Development | 35.7M | 37.53M | 41.02M | 35.36M | 25.72M |
| Selling, General & Admin | 11.43M | 14.34M | 16.12M | 19.33M | 17.56M |
| Operating Expenses | 47.63M | 32.24M | 44.13M | 49.75M | 41.02M |
| Depreciation & Amortization | 669.43K | 596.6K | 567.78K | 485.11K | 419.48K |
| EBITDA | (44.94M) | (28.84M) | (42.06M) | (45.55M) | (45.16M) |
| EBITDA Margin | — | — | -66674.3% | -27476.7% | -153976.3% |
| Operating Income | (47.63M) | (32.24M) | (44.59M) | (52.91M) | (48.26M) |
| Operating Margin | — | — | -70685.6% | -31911.4% | -164525.5% |
| Interest Income | 109.39K | 608.68K | 3.8M | 3.2M | 1.77M |
| Interest Expense | 24.77K | 45.25K | 35.63K | 20.66K | 37.69K |
| Other Income / Expenses | 2M | 2.75M | 1.93M | 6.85M | 2.64M |
| Income Before Tax | (45.63M) | (29.48M) | (42.67M) | (46.06M) | (45.62M) |
| Pre-Tax Margin | — | — | -67630.7% | -27781.8% | -155540.2% |
| Income Tax Expense | 0 | 0 | 0 | 5.22K | 12.28K |
| Net Income | (45.63M) | (29.48M) | (42.67M) | (46.06M) | (45.63M) |
| Net Margin | — | — | -67630.7% | -27785.0% | -155582.1% |
| EPS (Basic) | (1.10) | (0.61) | (0.78) | (0.78) | (0.66) |
| EPS (Diluted) | (1.10) | (0.61) | (0.78) | (0.78) | (0.66) |
| Weighted Avg Shares | 41.63M | 44.21M | 54.94M | 58.92M | 67.29M |
| Weighted Avg Shares (Diluted) | 41.63M | 44.21M | 54.94M | 58.92M | 67.29M |
InflaRx N.V.
NASDAQ:IFRX
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.